[1] Riva P,Franceschi G,Frattarelli M,et al.131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malig-nant glioma:Phase I and II Study[J].Acta Oncologica,1999,38(3):351-359.
[2] Riva P,Franceschi G,Riva N,et al.Role of nuclear medicine in the treatment of malignant gliomas:the locoregional radioimmunotherapy approach[J].Eur J Nucl Med,2000,27(5):601-609.
[3] Santis RD,Anastasi AM,alessio VD.et al. Novel antitenascin antibody with increased tumour localisation for pretargeted antibodyguided radioimmunotherapy (PAGRITRR)[J].Br J Cancer,2003,88(07):996-1003.
[4] Akabani G,Cokgor I,Coleman RE,et al.Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy[J].Int J Radia Oncol Biol Phys,2000,46(4):947-958.
[5] Cokgor I,Akabani G,Kuan CT,et al.Phase I trial results of iodine-131 labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas[J].J Clin Oncol,2000,18(22):3862-3872.
[6] Goetz C,Rive P,Poepperl G,et al.Locoregional radioimmunotherapy in selected patients with malignant glioma:experience,side effects and survival times[J].J Neuro Oncol,2003,62:321-328.
[7] Mahesparan R,Read TA,Lund-Johansen M,et al.Expression of extracellular matrix components in a highly infiltrative in vivo glioma model[J].Acta Neuropathologica,2003,105(1):49-57.
[8] Akabani G,Reist CJ,Cokgor I,et al.Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors[J]. J Nucl Med,1999,40(4):631-638.
[9] Hasegawa K,Yoshida T,Matsumoto K,et al.Differential expression of tenascin-C and tenascin-X in human astrocytomas[J].Acta Neu-ropathologica,1997,93:431-437.
[10] Popperl G,Gotz C,Gildehaus FJ,et al.Initial experiences with adjuvant locoregional radioimmunotherapy using 131I-labeled monoclonal antibodies against tenascin(BC-4) for treatment of glioma (WHO IIIand TV)[J].Nuklearmedizin,2002,41(3):120-128.
[11] Reardon DA,Akabani G,Edward CR,et al.Phase II trial of murine 131I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas[J].J Clin Oncol,2002,20(5):1389-1397.
[12] Hopkins K,Chandler C,Eatough J,et al.Direct injection of 90Y-MoAbs into glioma tumor resection cavities leads to limited diffusion of the radioimmunoconjugates into normal brain parenchyma:a model to estimate absorbed radiation dose[J].Int J Radiat Oncol Biol Phys,1998,40(4):835-844.
[13] Riva P,Franceschi G,Frattarelli M,et al.Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y:a Phase I study[J].Clin Cancer Res,1999,5:3275s-3280s.
[14] Paganelli G,Grana C,Chinol M,et al.Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin[J].Eur J Nucl Med,1999,26(4):348-357.
[15] Grana C,Chinol M,Robertson C.Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients:a pilot study[J].Br J Cancer,2002,86:207-212.
[16] Hauck ML,Larsen RH,Welsh PC,et al.Cytotoxicity of α-particle emitting astatine-211-labelled antibody in tumour spheroids:no effect of hyperthermia[J].Br J Cancer,1998,77(5):753-759.
[17] Zalutsky MR,Zhao XG,Alston KL,et al.High-level production of α-particle emitting 211At and preparation of 211At labeled antibodies for clinical use[J].J Nucl Med,2001,42(10):1508-1515.
[18] Imam SK.Advancement in cancer therapy with alpha-emitters:a review[J].Int J Radiat Oncol Biol Phys,2001,51(1):271-278.